Distributor inventory | Tablet

Management of type 2 diabetes mellitus to control post-meal (postprandial) blood glucose; used alone or with other antidiabetic medicines along with diet and exercise.

Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine. This reduces the rise in blood glucose after meals and helps improve overall glycaemic control.

Oral tablet. Usually taken with the first bite of each main meal (as prescribed). Swallow with water; do not crush/chew unless advised. Follow diabetic diet and exercise plan; monitor blood glucose regularly.

Flatulence, abdominal pain, diarrhoea, bloating, nausea

Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in gastrointestinal disorders (e.g., inflammatory bowel disease, intestinal obstruction, chronic intestinal disease) and in significant liver impairment. Risk of hypoglycaemia increases when combined with insulin or sulfonylureas—if low sugar occurs, treat with glucose/dextrose (not sucrose) because absorption of sucrose is delayed. Consult doctor in elderly and if you have kidney/liver disease.

Insulin, sulfonylureas (e.g., glimepiride, gliclazide) may increase hypoglycaemia risk; corticosteroids and thyroid hormones may reduce glycaemic control; intestinal adsorbents/digestive enzymes may reduce effect; other antidiabetic drugs may have additive glucose-lowering effects.

Store at room temperature (below 25°C), protected from moisture and light. Keep in original blister pack and out of reach of children.

Voglib 0.3 Tablet, Volibo 0.3 Tablet, Vobose 0.3 Tablet, Voglistar 0.3 Tablet, Vogli 0.3 Tablet